-
Nov 26, 2024 | 
healio.com | Gabrielle Capaldo |Kristen Dowd |Amy S. Paller
You've successfully added Dermatitis to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: The total infection rate among dupilumab-treated patients was 101 per 100 patient-years (PY) in the 52-week study.
-
Nov 15, 2024 | 
healio.com | Gabrielle Capaldo |Kristen Dowd |Amy S. Paller
You've successfully added Pediatric Dermatology to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: By week 76, over 82% of patients treated with 15 mg or 30 mg of upadacitinib reached EASI 75. Upadacitinib maintained a safety profile consistent with previous studies.
-
Oct 23, 2024 | 
jamanetwork.com | Amy S. Paller |Pedro Mendes-Bastos |Elaine Siegfried |Lawrence F. Eichenfield
Key PointsQuestion
Is the efficacy of upadacitinib maintained with long-term treatment with an acceptable adverse event profile in adolescents with moderate to severe atopic dermatitis?
-
Jul 13, 2024 | 
dermatologytimes.com | Emma Andrus |Amy S. Paller
Amy Paller, MD, is the chair of dermatology at Northwestern Feinberg School of Medicine and a pediatric dermatologist from Chicago. At the 2024 Society for Pediatric Dermatology (SPD) Annual Meeting in Toronto, Ontario, Canada, Paller presented a session alongside colleagues Esteban Fernandez Faith, MD, Nationwide Children's Hospital; and Leo Shmuylovich, MD, PhD, Washington University.
-
Jun 20, 2024 | 
healio.com | Gabrielle Capaldo |Kristen Dowd |Amy S. Paller
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: AD affected more than 35% body surface area of study participants. Ruxolitinib plasma concentrations were 98.2 nm, which falls well below immunosuppression levels.
-
Jun 10, 2024 | 
dermatologytimes.com | Kaitlyn Bader |Amy S. Paller
“For most of our patients, topical steroids remain the mainstay of treatment, but for many of them, particularly when there are some nervous parents, we certainly want to have alternatives that are non-steroidal,” said Amy Paller, MD, in an interview at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema (RAVE) Conference in Chicago, Illinois.
-
May 2, 2024 | 
healio.com | Rebecca Forand |Kristen Dowd |Amy S. Paller
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Stigma regarding their chronic skin diseases was reported by 73% of pediatric patients in this cross-sectional study. Higher disease visibility was correlated with stigma, depression, QOL decline and anxiety.
-
Apr 2, 2024 | 
dermatologytimes.com | Amy S. Paller |Heidi Anne Duerr
“Take bone health very seriously,” Amy S. Paller, MS, MD, advised colleagues in an exclusive interview with Dermatology Times. Paller is chair in the department of dermatology, director of Skin Biology and Diseases Resource-Based Center, and the Walter J. Hamlin Professor of Dermatology at Northwestern University Feinberg School of Medicine.
-
Mar 31, 2024 | 
healio.com | Kristen Dowd |Amy S. Paller
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: 38% of boys and 52% of girls aged younger than 12 years with atopic dermatitis were above the 50th height percentile. On the other hand, 50% of boys and 51% of girls were above the 50th weight percentile.
-
Mar 20, 2024 | 
jamanetwork.com | Amy S. Paller |Barry Ladizinski |Pedro Mendes-Bastos |Elaine Siegfried
Reanalysis of Study After Removal of Participants in 1 Trial of Upadacitinib for Atopic Dermatitis Upadacitinib Treatment in Adolescents With Atopic Dermatitis Amy S. Paller, MD, MS; Barry Ladizinski, MD, MPH, MBA; Pedro Mendes-Bastos, MD; Elaine Siegfried, MD; Weily Soong, MD; Vimal H. Prajapati, MD; Peter Lio, MD; Jacob P. Thyssen, MD, PhD, DmSci; Eric L. Simpson, MD, MCR; Andrew M. Platt, PhD; Eliza M. Raymundo, MD; Jianzhong Liu, MD, MS; Brian M.
